{"id":"insulin-degludec-injection","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Insulin degludec is a ultra-long-acting insulin analog engineered with a 16-carbon fatty acid chain that enables multi-hexamer formation and subcutaneous depot formation, resulting in an exceptionally long half-life of approximately 25 hours and a duration of action exceeding 42 hours. It binds to the human insulin receptor with similar affinity to human insulin, activating downstream signaling pathways that increase glucose uptake in muscle and adipose tissue and inhibit gluconeogenesis in the liver. This extended duration allows for once-daily dosing with stable, predictable glucose-lowering effects.","oneSentence":"Insulin degludec is a long-acting basal insulin that binds to the insulin receptor to promote glucose uptake and utilization in peripheral tissues while suppressing hepatic glucose production.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:48:33.999Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT07173712","phase":"PHASE4","title":"Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Yanbing Li","startDate":"2026-03-15","conditions":"Type 2 Diabetes","enrollment":324},{"nctId":"NCT07387003","phase":"PHASE2","title":"Evaluate the Efficacy and Safety of GZR101-80 Injection in Patients With Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Gan & Lee Pharmaceuticals.","startDate":"2026-03-20","conditions":"Type 2 Diabetes (T2DM)","enrollment":300},{"nctId":"NCT07376200","phase":"PHASE1","title":"Single-ascending Dose Study of HEC-151 Injection","status":"NOT_YET_RECRUITING","sponsor":"Sunshine Lake Pharma Co., Ltd.","startDate":"2026-03-11","conditions":"Healthy Adult Male","enrollment":81},{"nctId":"NCT04770532","phase":"PHASE3","title":"A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Use Daily Insulin","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-03-05","conditions":"Diabetes Mellitus, Type 2","enrollment":526},{"nctId":"NCT04848480","phase":"PHASE3","title":"A Research Study to Compare a New Weekly Insulin, Insulin Icodec, and an Available Daily Insulin, Insulin Degludec, Both in Combination With Mealtime Insulin in People With Type 1 Diabetes (ONWARDS 6)","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-04-30","conditions":"Diabetes Mellitus, Type 1","enrollment":582},{"nctId":"NCT04588259","phase":"PHASE3","title":"Research Study to Compare a New Medicine \"Fast-acting Insulin Aspart\" to Another Medicine \"Insulin Aspart\" in Chinese People With Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2020-10-09","conditions":"Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":331},{"nctId":"NCT05417841","phase":"NA","title":"Safety and Efficacy of Insulin Degludec/Insulin Aspart in Patients With T2DM","status":"COMPLETED","sponsor":"Beijing Hospital","startDate":"2023-03-23","conditions":"Type 2 Diabetes Mellitus","enrollment":218},{"nctId":"NCT07018453","phase":"PHASE2","title":"A Study Comparing SHR-3167 and Insulin Degludec in Type 2 Diabetic Subjects Treated With Basal Insulin With or Without Oral Antidiabetic Drugs","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2025-07-16","conditions":"Type 2 Diabetes Mellitus","enrollment":173},{"nctId":"NCT05413369","phase":"PHASE3","title":"iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2022-07-07","conditions":"Type 2 Diabetes Mellitus","enrollment":582},{"nctId":"NCT07032688","phase":"PHASE1","title":"A Clinical Study to Evaluate the Pharmacokinetic and Pharmacodynamics Properties of of SHR-3167 in Subjects With Type 2 Diabetes","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2025-08-11","conditions":"Type 2 Diabetes","enrollment":55},{"nctId":"NCT04760626","phase":"PHASE3","title":"A Research Study to Compare a New Weekly Insulin, Insulin Icodec Used With DoseGuide App, and Daily Insulins in People With Type 2 Diabetes Who Have Not Used Insulin Before","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-03-01","conditions":"Diabetes Mellitus, Type 2","enrollment":1085},{"nctId":"NCT07146347","phase":"PHASE1","title":"Comparison Study of Insulin GZR4 With Insulin Degludec","status":"RECRUITING","sponsor":"Gan and Lee Pharmaceuticals, USA","startDate":"2025-08-15","conditions":"Type 2 Diabetes","enrollment":14},{"nctId":"NCT05463744","phase":"PHASE3","title":"A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2022-08-12","conditions":"Type 1 Diabetes, Diabetes","enrollment":692},{"nctId":"NCT06288412","phase":"PHASE1","title":"A Study to Test How a New Long-acting Insulin Works in the Body of Patients With Type 2 Diabetes During Exercise and Prolonged Fasting","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2024-02-26","conditions":"Diabetes Mellitus, Type 2","enrollment":30},{"nctId":"NCT04974528","phase":"PHASE3","title":"Afrezza® INHALE-1 Study in Pediatrics","status":"COMPLETED","sponsor":"Mannkind Corporation","startDate":"2021-09-29","conditions":"Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":319},{"nctId":"NCT06925334","phase":"PHASE4","title":"A Study Comparing Degu Insulin Liraglutide Injection With Premixed Insulin on the Prognosis of Diabetes Mellitus","status":"ENROLLING_BY_INVITATION","sponsor":"Beijing Tsinghua Chang Gung Hospital","startDate":"2024-05-20","conditions":"Type 2 Diabetic Patients","enrollment":170},{"nctId":"NCT05243628","phase":"PHASE4","title":"Afrezza With Basal Combination (ABC): Afrezza® Combined With AID Pump or Insulin Degludec in Adults With Type 1 Diabetes","status":"COMPLETED","sponsor":"Mannkind Corporation","startDate":"2022-03-31","conditions":"Type 1 Diabetes","enrollment":33},{"nctId":"NCT04538352","phase":"PHASE4","title":"Transition From Basal/Bolus to Once-weekly Subcutaneous Semaglutide and Basal Insulin in Patients With T2D","status":"COMPLETED","sponsor":"The Cleveland Clinic","startDate":"2021-01-18","conditions":"Type 2 Diabetes","enrollment":60},{"nctId":"NCT06202079","phase":"PHASE2","title":"A Trial Comparing the Efficacy and Safety of GZR4 Injection Versus Insulin Degludec in Subjects with Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Gan and Lee Pharmaceuticals, USA","startDate":"2023-08-11","conditions":"Diabetes Mellitus, Type 2","enrollment":179},{"nctId":"NCT06199505","phase":"PHASE2","title":"A Trial Comparing Efficacy and Safety of GZR101 and IDegAsp in Insulin Naïve or Insulin Treated Subjects with T2DM","status":"COMPLETED","sponsor":"Gan and Lee Pharmaceuticals, USA","startDate":"2023-11-21","conditions":"Type 2 Diabetes","enrollment":153},{"nctId":"NCT04795531","phase":"PHASE3","title":"A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 3)","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-03-24","conditions":"Diabetes Mellitus, Type 2","enrollment":588},{"nctId":"NCT06559722","phase":"PHASE3","title":"A Trial Investigating the Efficacy and Safety of Insulin Degludec/Liraglutide Injection in Subjects With Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Tonghua Dongbao Pharmaceutical Co.,Ltd","startDate":"2024-08","conditions":"Type 2 Diabetes","enrollment":510},{"nctId":"NCT06556641","phase":"PHASE1","title":"A Clinical Study of GZR33 and GZR101 in Healthy Subjects","status":"COMPLETED","sponsor":"Gan and Lee Pharmaceuticals, USA","startDate":"2022-12-17","conditions":"Healthy Subjects","enrollment":28},{"nctId":"NCT05904743","phase":"PHASE4","title":"INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes","status":"COMPLETED","sponsor":"Mannkind Corporation","startDate":"2023-07-07","conditions":"Diabetes Mellitus, Type 1","enrollment":141},{"nctId":"NCT06449703","phase":"PHASE1","title":"A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide in Healthy Chinese Subjects","status":"RECRUITING","sponsor":"Tonghua Dongbao Pharmaceutical Co.,Ltd","startDate":"2024-05-06","conditions":"Healthy","enrollment":44},{"nctId":"NCT06408532","phase":"PHASE4","title":"The Efficacy and Safety of Insulin Degludec/Liraglutide Combination (IDegLira) in Patients With Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2024-04-30","conditions":"Diabetes Mellitus, Type 2","enrollment":256},{"nctId":"NCT04623086","phase":"PHASE4","title":"Comparison of Glargine to Degludec Insulin Transition With or Without a Bridging Glargine Dose","status":"COMPLETED","sponsor":"University of Washington","startDate":"2020-02-14","conditions":"Type 1 Diabetes","enrollment":59},{"nctId":"NCT05360537","phase":"PHASE4","title":"Effects of Degludec/Liraglutide on Time in Range, Inflammation and Endothelial Function vs Insulin Basal Bolus in Diabetic Inpatients","status":"COMPLETED","sponsor":"University of Palermo","startDate":"2021-04-01","conditions":"Diabetes Mellitus, Type 2","enrollment":100},{"nctId":"NCT03862716","phase":"PHASE3","title":"Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IDegLira","status":"COMPLETED","sponsor":"Population Health Research Institute","startDate":"2019-04-23","conditions":"Type 2 Diabetes Mellitus","enrollment":159},{"nctId":"NCT06057077","phase":"PHASE1, PHASE2","title":"Semaglutide GLP1 Agonists With Degludec Basal-bolus Insulin in Early Type 1 Diabetes to Basal-bolus","status":"UNKNOWN","sponsor":"Ministry of Health, Saudi Arabia","startDate":"2024-01-01","conditions":"Type 1 Diabetes","enrollment":120},{"nctId":"NCT03377699","phase":"PHASE3","title":"Research Study Comparing Insulin Degludec to Insulin Detemir, Together With Insulin Aspart, in Pregnant Women With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2017-11-22","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":225},{"nctId":"NCT04663282","phase":"PHASE2","title":"A Trial of INS068 in Patients With Type 2 Diabetes Not Adequately Controlled With One or Two Oral Antidiabetics","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2021-02-04","conditions":"Type 2 Diabetes","enrollment":179},{"nctId":"NCT04075513","phase":"PHASE4","title":"Comparison of Glucose Values and Variability Between TOUJEO and TRESIBA During Continuous Glucose Monitoring in Type 1 Diabetes Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2019-10-09","conditions":"Type 1 Diabetes Mellitus","enrollment":343},{"nctId":"NCT04450394","phase":"PHASE2","title":"A Phase 2 Study of LY3209590 in Participants With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-07-01","conditions":"Type 2 Diabetes Mellitus","enrollment":278},{"nctId":"NCT03668808","phase":"PHASE4","title":"Comparison of Insulin Degludec With Insulin Glargine U100 for Adults With Type 1 Diabetes Crossing Multiple Time Zones.","status":"COMPLETED","sponsor":"Sansum Diabetes Research Institute","startDate":"2018-11-16","conditions":"Diabetes Mellitus, Type 1","enrollment":25},{"nctId":"NCT04450407","phase":"PHASE2","title":"A Study of LY3209590 in Participants With Type 1 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-07-06","conditions":"Type 1 Diabetes Mellitus","enrollment":266},{"nctId":"NCT05576298","phase":"PHASE1","title":"A Clinical Study Comparing the Pharmacokinetics and Pharmacodynamic Characteristics of Insulin Degludec Injection (RD15003) and Insulin Degludec Injection (Tresiba®) in Healthy Subjects","status":"COMPLETED","sponsor":"Sunshine Lake Pharma Co., Ltd.","startDate":"2021-10-08","conditions":"Type 2 Diabetes","enrollment":46},{"nctId":"NCT05429359","phase":"NA","title":"cArdiopulmonary exerCise Test Assessing Multiple biOmarkers and Hormones iN Type 1 diabetEs Under Different Circumstances","status":"UNKNOWN","sponsor":"University Hospital, Antwerp","startDate":"2022-10-01","conditions":"Diabetes Mellitus, Type 1","enrollment":50},{"nctId":"NCT03557892","phase":"NA","title":"Sensor-augmented Pump Versus Multiple Daily Injections With Degludec as Basal Insulin for Insulin Therapy in Type 1 Diabetes","status":"COMPLETED","sponsor":"Azienda Ospedaliero-Universitaria Careggi","startDate":"2018-04-01","conditions":"Diabetes Mellitus, Type 1","enrollment":28},{"nctId":"NCT05261997","phase":"NA","title":"Endotherapy for Painless Chronic Pancreatitis","status":"UNKNOWN","sponsor":"Changhai Hospital","startDate":"2022-03","conditions":"Pancreatitis, Chronic, Exocrine Pancreatic Insufficiency, Abdominal Pain","enrollment":60},{"nctId":"NCT03740919","phase":"PHASE3","title":"A Study Comparing LY900014 to Insulin Lispro (Humalog) in Children and Adolescents With Type 1 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2019-04-07","conditions":"Type 1 Diabetes Mellitus","enrollment":751},{"nctId":"NCT03078478","phase":"PHASE3","title":"A Trial Comparing the Efficacy and Safety of Insulin Degludec and Insulin Glargine 300 Units/mL in Subjects With Type 2 Diabetes Mellitus Inadequately Treated With Basal Insulin With or Without Oral Antidiabetic Drugs","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2017-03-13","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":1609},{"nctId":"NCT03400501","phase":"EARLY_PHASE1","title":"Reducing the Risk of Metabolic Decompensation in Diabetic Adolescents by Supervised School Administration of Insulin","status":"COMPLETED","sponsor":"Yale University","startDate":"2017-10-01","conditions":"Type 1 Diabetes Mellitus","enrollment":32},{"nctId":"NCT04955834","phase":"PHASE3","title":"A Clinical Study of Insulin Degludec Injection in Subjects With Type 2 Diabetes","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2021-07-27","conditions":"Type 2 Diabetes","enrollment":344},{"nctId":"NCT03987191","phase":"PHASE4","title":"Insulin Pump to Multiple Daily Injection Transition Clinical Trial","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2020-01-10","conditions":"Type 1 Diabetes","enrollment":38},{"nctId":"NCT03736785","phase":"PHASE2","title":"A Study of LY3209590 in Participants With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2018-11-15","conditions":"Type 2 Diabetes Mellitus","enrollment":399},{"nctId":"NCT04409587","phase":"PHASE4","title":"Basal Insulin Glycemic ControL With DEglugec vs Aspart Via Pump","status":"COMPLETED","sponsor":"Mountain Diabetes and Endocrine Center","startDate":"2018-04-12","conditions":"Type1 Diabetes Mellitus","enrollment":59},{"nctId":"NCT03687827","phase":"PHASE4","title":"A Research Study to Compare the Effect of Insulin Degludec and Insulin Glargine on Blood Sugar Levels in People With Type 2 Diabetes - the SWITCH PRO Study","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2018-10-02","conditions":"Diabetes Mellitus, Type 2","enrollment":498},{"nctId":"NCT04196231","phase":"PHASE4","title":"Durability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes (BEYOND)","status":"COMPLETED","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2019-11-27","conditions":"Type 2 Diabetes","enrollment":258},{"nctId":"NCT02670915","phase":"PHASE3","title":"Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Children and Adolescents With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2016-05-04","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":834},{"nctId":"NCT02762578","phase":"PHASE3","title":"Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2016-05-03","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":543},{"nctId":"NCT02738151","phase":"PHASE4","title":"Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-05-19","conditions":"Diabetes Mellitus, Type 2","enrollment":929},{"nctId":"NCT03463564","phase":"PHASE4","title":"Insulin Pump vs Multiple Daily Injections of Insulin and Glyco-metabolic Control in Type 1 Diabetic Patients","status":"RECRUITING","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2016-01","conditions":"Type 1 Diabetes Mellitus","enrollment":150},{"nctId":"NCT02298192","phase":"PHASE3","title":"A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) in Subjects With Type 2 Diabetes Mellitus Using Two Different Titration Algorithms","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2014-11-21","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":420},{"nctId":"NCT00614055","phase":"PHASE2","title":"Comparison of Two NN5401 Formulations Versus Insulin Glargine, All in Combination With Metformin in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2008-01","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":178},{"nctId":"NCT00613951","phase":"PHASE2","title":"Comparison of Two NN5401 Formulations Versus Biphasic Insulin Aspart 30, All in Combination With Metformin in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2008-01","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":182},{"nctId":"NCT00611884","phase":"PHASE2","title":"Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Metformin in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2008-01","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":245},{"nctId":"NCT00612040","phase":"PHASE2","title":"Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Insulin Aspart in Subjects With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2008-01","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":178},{"nctId":"NCT00841087","phase":"PHASE2","title":"Comparison of NN1250 Versus Insulin Detemir, Both Combined With Insulin Aspart in Subjects With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2009-01","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":65},{"nctId":"NCT01138488","phase":"PHASE1","title":"A Trial Investigating the Total Exposure of NN5401 (Insulin Degludec/Insulin Aspart) in Children, Adolescents and Adult Subjects With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2010-06","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":38},{"nctId":"NCT01002768","phase":"PHASE1","title":"Comparison of Hypoglycaemic Response Between NN1250 and Insulin Glargine in Type 1 Diabetics","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2009-10","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":28},{"nctId":"NCT01151072","phase":"PHASE1","title":"A Trial Comparing the Effect of NN1250 After Different Routes of Injection in Healthy Subjects","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2010-06","conditions":"Diabetes, Healthy","enrollment":20},{"nctId":"NCT02360254","phase":"","title":"Effects of Shifting From Twice Daily Insulin Glargine or Detemir to Once Daily Insulin Degludec in Type 1 Diabetes","status":"COMPLETED","sponsor":"University of Padova","startDate":"2015-01","conditions":"Type 1 Diabetes Mellitus","enrollment":26},{"nctId":"NCT01868581","phase":"PHASE1","title":"Bioequivalence Between Two Explorative Insulin Degludec Formulations and Between Two Explorative IDegAsp Formulations in Healthy Subjects","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2008-05","conditions":"Diabetes, Healthy","enrollment":58},{"nctId":"NCT01125553","phase":"PHASE1","title":"A Comparison Between Two Formulations of NN5401 in Healthy Subjects","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2010-05","conditions":"Diabetes, Healthy","enrollment":26},{"nctId":"NCT01455142","phase":"PHASE1","title":"A Trial to Test for Bioequivalence Between NN1045 and NN5401 in Subjects With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2011-10","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":32},{"nctId":"NCT01193387","phase":"PHASE1","title":"Comparison of Two Identical NN1250 Formulations in Healthy Volunteers","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2010-08","conditions":"Diabetes, Healthy","enrollment":26},{"nctId":"NCT01916174","phase":"PHASE1","title":"A Trial to Demonstrate Bioequivalence Between Two Insulin Degludec/Liraglutide Formulations, B5 and V2 in Healthy Subjects","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2013-08","conditions":"Diabetes, Diabetes Mellitus, Type 2, Healthy","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Insulin Degludec Injection","genericName":"Insulin Degludec Injection","companyName":"Jiangsu HengRui Medicine Co., Ltd.","companyId":"jiangsu-hengrui-medicine-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Insulin degludec is a long-acting basal insulin that binds to the insulin receptor to promote glucose uptake and utilization in peripheral tissues while suppressing hepatic glucose production. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}